

News Release

Biofrontera AG Notice of Third Quarter Results 2015

Leverkusen, Germany, 12 November 2015 - Biofrontera AG (AIM: B8F), the biopharmaceutical company focusing on sun-induced skin cancer, will on 20 November 2015 announce its results for the nine months period ending 30 September 2015.

A conference call for shareholders and interested investors will be held on 20 November 2015 at the following times:

3.00pm CET (2.00pm UK) conference call in German:
Dial-in number: +49-(0)69-271340 166 (*room number not required*)

4.30pm CET (3.30pm UK) conference call in English:
Dial-in number Germany: +49-(0)69 271 340 801
Dial-in number UK: +44 203 36 45 807
Dial-in number USA: +1 240 64 50 345
Dial-in number USA (New York): +1 646 66 37 901
Conference code: 30057714#

Ends

Enquiries, please contact:

Biofrontera AG	+49 (0) 214 87 63 2 0
Thomas Schaffer, Chief Financial Officer	press@biofrontera.com
	www.biofrontera.com
IR Germany: Brainwell Asset Solutions	+49 (0) 152 08931514
Jürgen Benker	
Nomad and Broker: Shore Capital	+44(0) 20 7408 4090
Bidhi Bhoma / Toby Gibbs	
IR UK: Seton Services	+44(0) 20 7603 6797
Toni Vallen	
Financial PR: Gable Communications	+44(0) 20 7193 7463
John Bick	+44 (0)7872 061007

Background:

The **Biofrontera Group** (FSE/AIM: B8F, ISIN DE0006046113) is a biopharmaceutical company specialising in the development, sale and distribution of drugs and medical cosmetics for the care and treatment of skin diseases. Biofrontera's most important product is Ameluz[®], a prescription drug which is approved in Europe for the treatment of mild and moderate actinic keratosis (superficial skin cancer) with photodynamic therapy (light therapy). Biofrontera is the first German pharmaceutical start-up company to obtain centralised approval for a drug it has developed itself. The company also plans for Ameluz[®] to be

News Release

approved for basal cell carcinoma and is currently preparing for approval in other countries, especially in the largest pharmaceutical market in the world, the United States.

The company also markets the Belixos[®] dermatological range of cosmetics. Belixos[®] products, a cream, a gel and a scalp tonic, contain combinations of active substances extracted from plants, relieve itching and redness and are used for the regenerative care of chronic skin conditions such as atopic dermatitis or psoriasis. The Belixos[®] Protect, a daily skincare for sun-damaged skin, complements this dermo-cosmetic line. All products are available through Amazon.

The Biofrontera Group was established in 1997 by Prof. Dr Hermann Lübbert, the Chairman of the company's Management Board, and has its headquarters in Leverkusen, Germany.

www.biofrontera.com

This communication expressly or implicitly contains certain forward-looking statements concerning the business activities of Biofrontera AG. These forward-looking statements reflect the opinion of Biofrontera at the time of this communication and involve certain known and unknown risks. The actual results achieved by Biofrontera may differ significantly from future results or performances which are published in its forward-looking statements. Biofrontera assumes no responsibility to update its forward-looking statements.